The position of transarterial chemoembolization with drug-eluting beads and yttrium-90 transarterial radioembolization in patients with hepatocellular carcinoma: Consensus statements from a Delphi-method expert panel in Turkey.

PURPOSE: Clinical studies conducted in different geographic regions using different methods to compare transarterial chemoembolization (TACE) and transarterial radioembolization (TARE) have demonstrated discordant results. Meta-analyses in this field indicate comparable overall survival (OS) with TACE and TARE, while reporting a longer time to progression and a higher downstaging effect with TARE treatment. In terms of isolated procedure costs, treatment with TARE is 2 to 3 times more, and in some countries even more, expensive than TACE. However, relevant literature indicates that TARE is more advantageous compared to TACE regarding the need for repeat procedures, costs of complication management, total hospital stay and quality of life. Heterogeneity of hepatocellular carcinoma (HCC) patients as well as the shortcomings of clinical classifications, randomized clinical trials and cost-effectiveness studies make it difficult to choose between treatment alternatives in this field. As in other countries, these challenges lead to differences in treatment choice across different centers in Turkey. METHODS: The present expert panel used two round modified Delphi method to investigate the resources and clinical parameters referenced while selecting patients for drug-eluting beads (DEB)-TACE and TARE treatment modalities in Turkish clinical practice. The cost-effectiveness parameters and comparisons of these treatments have also been evaluated at a prediction level. RESULTS: The panelists stated that they most commonly use the BCLC staging system for the management of HCC patients in Turkey. However, they did not find any of the staging systems or treatment guidelines sufficient enough for their clinical practice in terms of covering the down-staging intent of treatments. Since living donor transplant preference is higher in Turkey than the rest of the Western countries, down-staging treatments are thought to be more prioritized in Turkey than that in other Western countries. The panelists reached a consensus that TARE may provide improved OS and reduce the number of repeat procedures compared to DEB-TACE in intermediate-stage patients with a single tumor spanning a diameter above 5 cm who experience recurrence after previous treatment with TACE and most TACE-naïve patient groups in intermediate stage. CONCLUSION: Based on the consensus on OS and the number of procedures, the panelists assumed that TARE would be more cost-effective than DEB-TACE in most groups of TACE-naïve patients in intermediate stage and in those with a single tumor spanning a diameter above 5 cm. It was also stated that the predicted cost-effectiveness advantage of TARE could be more pronounced in patients with a tumor diameter greater than 7 cm.

Minimally invasive treatment of giant haemangiomas of the liver: embolisation with bleomycin.

PURPOSE: The management of patients with giant haemangioma of the liver remains controversial. Although the usual treatment method for symptomatic giant haemangioma is surgery, the classical paradigm of operative resection remains. In this study, we evaluated the symptomatic improvement and size-reduction effect of embolisation with bleomycin mixed with lipiodol for the treatment of symptomatic giant hepatic haemangioma. METHODS: This study included 26 patients [21 female, five male; age 41-65 years (mean 49.83 ± 1.53)] with symptomatic giant haemangioma unfit for surgery and treated with selective embolisation by bleomycin mixed with lipiodol. The patients were followed-up (mean 7.4 ± 0.81 months) clinically and using imaging methods. Statistical analysis was performed using SPSS version 16.0, and p < 0.05 was considered to indicate statistical significance. RESULTS: Embolisation of 32 lesions in 26 patients was performed. The mean volume of the haemangiomas was 446.28 ± 88 cm(3) (range 3.39-1559 cm(3)) before intervention and 244.43 ± 54.38 cm(3) (range 94-967 cm(3)) after intervention. No mortality or morbidity related to the treatment was identified. Symptomatic improvement was observed in all patients, and significant volume reduction was achieved (p = 0.001). CONCLUSION: The morbidity of surgical treatment in patients with giant liver hemangioma were similar to those obtained in patients followed-up without treatment. Therefore, follow-up without treatment is preferred in most patients. Thus, minimally invasive embolisation is an alternative and effective treatment for giant symptomatic haemangioma of the liver.

Ventricular/paraventricular small arteriovenous malformations: role of embolisation with cyanoacrylate.

Arteriovenous malformations (AVMs) located in or near to ventricles have proven difficult to treat. We report the safety and efficacy of embolisation of these deep central lesions and describe the contribution of embolisation to multimodality treatment. Fourteen consecutive patients with small (less than 3 cm) ventricular/paraventricular AVMs arranged for possible embolisation to their nidi. All patients presented with intracranial haemorrhage. The AVMs ranged in size from 10 to 30 mm (average, 17 mm). Embolisations were performed using liquid adhesive (cyanoacrylate and iodised oil mixture at a ratio of less than 1:4) delivered by flow-guided microcatheters with the patient under general anaesthesia. One patient (7.1%) was considered unsuitable for embolisation, and another (7.1%) was not able to undergo embolisation because of the morphological features of the AVM feeders, while the remaining 12 could be embolised successfully. Six of 12 patients who underwent embolisation achieved complete occlusion of their AVMs (overall occlusion rate, 42.9%), while the remaining 6 were embolised partially with a 60-95% (mean = 80%) size reduction. One (8%) permanent neurological deficit resulted from embolisation. Endovascular therapy seems to make a significant contribution to the multimodality treatment of small AVMs located in the ventricle or paraventricular deep area. Embolisation alone permits complete cure in a large number of patients. It results in obliteration of a significant volume of the nidus in most of the remaining patients, which makes those nidi more vulnerable to subsequent multimodal therapy.